alosetron

Also known as GR68755, Lotronex®, 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one

Alosetron, sold under the brand name Lotronex among others, is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in females only.

Key facts

Drug.image: Alosetron.svg
Drug.image_class: skin-invert-image
Drug.width: 222
Drug.image2: Alosetron ball-and-stick model.png
Drug.image_class2: bg-transparent
Drug.tradename: Lotronex
Drug.MedlinePlus: a601230
Drug.DailyMedID: Alosetron
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: A03
Drug.ATC_suffix: AE01
Drug.legal_US: Rx-only
Drug.bioavailability

Article

8 sections

Contents

Medical uses
Efficacy
Contraindications
Adverse effects
Mechanism of action
History
Criticism of the FDA
References

Alosetron, sold under the brand name Lotronex among others, is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in females only.

It was patented in 1987 and approved for medical use in 2002. It is currently marketed by Prometheus Laboratories Inc. (San Diego). Alosetron was withdrawn from the market in 2000 owing to the occurrence of serious life-threatening gastrointestinal adverse effects, but was reintroduced in 2002 with availability and use restricted.